Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 306.5 EUR 2.51% Market Closed
Market Cap: 2.6B EUR

EV/EBITDA
Enterprise Value to EBITDA

9.9
Current
10.2
Median
12.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
9.9
=
Enterprise Value
2.7B EUR
/
EBITDA
268.1m EUR
EBITDA Growth EV/EBITDA to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBITDA: 395.4
9.9
11%
0.9
US
Eli Lilly and Co
NYSE:LLY
41.1
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.8
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
15%
0.9
CH
Roche Holding AG
SIX:ROG
10.8
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
127
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.3
3%
2.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
8.7
2-Years Forward
EV/EBITDA
8
3-Years Forward
EV/EBITDA
7.2